Article
Biochemistry & Molecular Biology
Michael E. Meyer, Arpit Doshi, Willma E. Polgar, Nurulain T. Zaveri
Summary: The development of SAR around substituted N-piperidinyl indole-based nociceptin opioid receptor (NOP) ligands led to the discovery of a novel series of 2-substituted N-piperidinyl indoles that provide selective NOP full agonists and bifunctional NOP full agonists-Mu-opioid (MOP) receptor partial agonists. The SAR in this study reveals that 2-substitution on the indole moiety affects the intrinsic activity and opioid receptor selectivity of these compounds compared to the 3-substituted counterparts. Molecular docking of these compounds in NOP homology model and MOP receptor structures provides insights into the observed differences in binding, functional profiles, and selectivity.
BIOORGANIC & MEDICINAL CHEMISTRY
(2023)
Article
Geriatrics & Gerontology
Marco Raffaele, Kristina Kovacovicova, Tommaso Biagini, Oriana Lo Re, Jan Frohlich, Sebastiano Giallongo, James D. Nhan, Antonino Giulio Giannone, Daniela Cabibi, Martin Ivanov, Anton B. Tonchev, Martin Mistrik, Matthew Lacey, Petr Dzubak, Sona Gurska, Marian Hajduch, Jiri Bartek, Tommaso Mazza, Vincenzo Micale, Sean P. Curran, Manlio Vinciguerra
Summary: The study identified MCOPB as a NOP ligand with tissue-specific senolytic effects, reducing the senescent cell burden in peripheral tissues but not affecting the central nervous system. Additionally, exposure to MCOPB led to changes in locomotion and lipid storage. Mechanistically, MCOPB treatment activated transcriptional networks involved in immune responses to external stressors, implicating Toll-like receptors (TLRs).
Article
Biochemistry & Molecular Biology
Giuliana Costanzo, Rita Turnaturi, Carmela Parenti, Salvatore Spoto, Silvia Piana, Maria Dichiara, Chiara Zagni, Anna Rita Galambos, Nariman Essmat, Agostino Marrazzo, Emanuele Amata, Mahmoud Al-Khrasani, Lorella Pasquinucci
Summary: In this study, we investigated the pharmacological properties of LP1 analogs both in vitro and in vivo to develop compounds with improved analgesic effects. By modifying the structure of the N-substituent of LP1, we found that compounds 3 and 7 displayed high binding affinity for the mu opioid receptor (MOR) and showed antagonist or agonist effects in different assays. Compound 7, as potent as LP1 and DAMGO, demonstrated analgesic effects in thermal and inflammatory pain models.
Article
Cell Biology
Qihui Guan, Renata Voltolini Velho, Alice Jordan, Sabrina Pommer, Irene Radde, Jalid Sehouli, Sylvia Mechsner
Summary: Endometriosis is a chronic inflammatory disease that affects millions of women worldwide. Chronic pelvic pain is a major issue in this condition, but current treatment options are not effective. Understanding pain mechanisms can help develop better therapeutic strategies, particularly specific analgesic options.
Article
Chemistry, Medicinal
Ying-Ting Hsu, Shen-Ren Chen, Yung-Chiao Chang, Hsiao-Fu Chang, Teng-Kuang Yeh, Jian-Ying Chuang, Horace H. Loh, Hsing-Pang Hsieh, Shau-Hua Ueng, Shiu-Hwa Yeh
Summary: The demand for a non-addictive analgesic medication is increasing due to clinical misuse. Compound 14 is a dual agonist of the mu opioid receptor (MOR) and nociceptin-orphanin FQ opioid peptide (NOP) receptor, providing pain relief at very small doses and reducing unwanted side effects. Evaluating its effects in wild type and humanized mice can help develop a safer prescription analgesic drug.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Chemistry, Medicinal
Davida Mirra, Giuseppe Spaziano, Renata Esposito, Debora Santonocito, Rosanna Filosa, Fiorentina Roviezzo, Gaetano Malgieri, Gianluca D'Abrosca, Pasquale Iovino, Luca Gallelli, Roberto Fattorusso, Carmelo Puglia, Bruno D'Agostino
Summary: This study aimed to improve the bioavailability of N/OFQ by developing solid lipid nanoparticles (SLNs) and tested its therapeutic efficacy for asthma. The results showed that N/OFQ-SLNs had positive effects on the inflammatory process and the mechanical properties of the airways, suggesting potential therapeutic benefits for asthmatic patients.
Article
Pharmacology & Pharmacy
Omar N. Al Yacoub, Stefano Tarantini, Yong Zhang, Anna Csiszar, Kelly M. Standifer
Summary: Traumatic brain injury (TBI) affects millions of people each year and is a leading cause of death and disability. This study suggests that the N/OFQ-NOP receptor pathway plays a significant role in regulating cerebral blood flow and injury markers in TBI, indicating that the NOP receptor could be a potential therapeutic target for TBI.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Guan-Yu Zhuo, Ming-Chi Chen, Tzu-Yu Lin, Shih-Ting Lin, Daniel Tzu-Li Chen, Cynthia Wei-Sheng Lee
Summary: We investigated the effects of opioids on the coexpressed mu-opioid (MOP) and nociceptin/orphanin FQ (NOP) receptors in human embryonic kidney (HEK) 293 cells. Our findings suggest that morphine, but not buprenorphine, facilitates the formation of MOP-NOP heterodimers and enhances their localization on lipid rafts. Moreover, morphine stimulates the phosphorylation of Erk1/2 in cells expressing MOP and MOP+NOP receptors, while buprenorphine appears to activate Erk1/2 solely through NOP receptors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Neurosciences
Wenfu Li, Zhiheng Ren, Ying Tang, Yixin Fu, Shizhu Sun, Ruxuan Ding, Jiawei Hou, Yunlin Mai, Bo Zhan, Yingxin Zhu, Wanhong Zuo, Jiang-Hong Ye, Rao Fu
Summary: Recent studies suggest that the stimulation of the rostromedial tegmental nucleus (RMTg) and the role of the nociceptin/orphanin FQ (N/OFQ) system may be involved in affective disorders and drug addiction. This study found that N/OFQ signaling contributes to changes in behavior and RMTg activity of rats during alcohol withdrawal. The deficiency of RMTg N/OFQ signaling mediates anxiety- and depression-like behaviors in alcohol withdrawn rats, and the intervention of the N/OFQ system may potentially help individuals with alcohol use disorders.
NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Neurosciences
Savannah Tollefson, Clara Stoughton, Michael L. Himes, Kaylynn E. Mckinney, Scott Mason, Roberto Ciccocioppo, Rajesh Narendran
Summary: This study investigated the relationship between nociceptin opioid peptide receptor (NOP) and relapse to alcohol in treatment-seeking individuals with alcohol use disorder (AUD). The results showed that individuals with AUD who drank heavily before the study had lower levels of NOP, which were also negatively correlated with drinking frequency and quantity. Individuals with AUD who relapsed had lower levels of NOP compared to those who abstained for 12 weeks. The study highlights the potential of investigating NOP-targeted medications for preventing relapse in individuals with AUD.
BIOLOGICAL PSYCHIATRY
(2023)
Article
Endocrinology & Metabolism
Jian Xiao, Jiandong Niu, Biao Xu, Run Zhang, Mengna Zhang, Nan Zhang, Kangtai Xu, Qinqin Zhang, Dan Chen, Yonghang Shi, Quan Fang, Ning Li
Summary: This study investigates the antinociceptive effects of NOP01 on orofacial pain and its possible mechanisms of action. The results suggest that NOP01 exerts significant antinociception in both peripheral and spinal levels through the NOP receptor. Notably, NOP01 may be a potential compound for developing peripherally restricted analgesics, as it cannot readily penetrate the blood-brain barrier.
Article
Biochemistry & Molecular Biology
Ning Li, Jian Xiao, Jiandong Niu, Mengna Zhang, Yonghang Shi, Bowen Yu, Qinqin Zhang, Dan Chen, Nan Zhang, Quan Fang
Summary: The combination of classical opioids and N/OFQ receptor (NOP) ligands may be effective in reducing side effects and improving pain relief, but the interaction between these two receptor ligands at the peripheral level is unclear. This study suggests that the peripheral agonist DAMGO-NH2 and its combination with NOP01 can effectively manage pain without affecting motor function in mice.
Article
Endocrinology & Metabolism
Xiao-Qing Hao, Zhi-Yuan Wang, Jian-Min Chen, Ning Wu, Jin Li
Summary: The study found that systemic activation of NOP receptors attenuated morphine antinociception to acute thermal stimuli, accelerated morphine-induced antinociceptive tolerance development in female mice, but did not significantly alter morphine-induced physical dependence.
METABOLIC BRAIN DISEASE
(2021)
Article
Chemistry, Medicinal
Renata Zajaczkowska, Ewelina Rojewska, Agata Ciechanowska, Katarzyna Pawlik, Katarzyna Ciapala, Magdalena Kocot-Kepska, Wioletta Makuch, Jerzy Wordliczek, Joanna Mika
Summary: Neuropathic pain is a complex and difficult clinical challenge. Despite the availability of various treatment options, many patients still experience ineffective pain relief. Recent research suggests that mirogabalin may provide analgesic effects through several indirect mechanisms.
Article
Zoology
Vanrohlu Nicy, Guruswami Gurusubramanian, Vikas K. Roy
Summary: Copper nanoparticles (CuNPs) have detrimental effects on male reproductive organs and epididymis in a dose and tissue dependent manner. Lower dose of CuNPs for a longer duration is safe for reproductive organs.
JOURNAL OF EXPERIMENTAL ZOOLOGY PART A-ECOLOGICAL AND INTEGRATIVE PHYSIOLOGY
(2023)
Article
Pharmacology & Pharmacy
David R. Maguire, Lisa R. Gerak, Gerta Cami-Kobeci, Stephen M. Husbands, Charles P. France, Barbara Belli, Peter Flynn
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2020)
Article
Substance Abuse
Meryem Grabski, H. Valerie Curran, David J. Nutt, Stephen M. Husbands, Stuart G. Ferguson, Marcus R. Munafo
DRUG AND ALCOHOL DEPENDENCE
(2020)
Article
Pharmacology & Pharmacy
Isaac J. Dripps, Ruizhuo Chen, Amanda M. Shafer, Kathryn E. Livingston, Alexander Disney, Stephen M. Husbands, John R. Traynor, Kenner C. Rice, Emily M. Jutkiewicz
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2020)
Article
Neurosciences
David R. Maguire, Lisa R. Gerak, Jesus J. Sanchez, Martin A. Javors, Alex Disney, Stephen M. Husbands, Charles P. France
NEUROPSYCHOPHARMACOLOGY
(2020)
Correction
Multidisciplinary Sciences
Weijiao Huang, Aashish Manglik, A. J. Venkatakrishnan, Toon Laeremans, Evan N. Feinberg, Adrian L. Sanborn, Hideaki E. Kato, Kathryn E. Livingston, Thor S. Thorsen, Ralf C. Kling, Sebastien Granier, Peter Gmeiner, Stephen M. Husbands, John R. Traynor, William I. Weis, Jan Steyaert, Ron O. Dror, Brian K. Kobilka
Article
Neurosciences
Vanessa Minervini, Alex Disney, Stephen M. Husbands, Charles P. France
PSYCHOPHARMACOLOGY
(2020)
Article
Pharmacology & Pharmacy
Sam Groom, Nina K. Blum, Alexandra E. Conibear, Alexander Disney, Rob Hill, Stephen M. Husbands, Yangmei Li, Lawrence Toll, Andrea Kliewer, Stefan Schulz, Graeme Henderson, Eamonn Kelly, Chris P. Bailey
Summary: This study confirmed that Compound 1 is a G protein-biased mu agonist that can induce substantial rapid receptor desensitisation in mammalian neurons. However, contrary to previous assumptions, the desensitisation effect of Compound 1 is dependent on G protein-coupled receptor kinase (GRK).
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Charles P. France, Gerard P. Ahern, Saadyah Averick, Alex Disney, Heather A. Enright, Babak Esmaeli-Azad, Arianna Federico, Lisa R. Gerak, Stephen M. Husbands, Benedict Kolber, Edmond Y. Lau, Victoria Lao, David R. Maguire, Michael A. Malfatti, Girardo Martinez, Brian P. Mayer, Marco Pravetoni, Niaz Sahibzada, Phil Skolnick, Evan Y. Snyder, Nestor Tomycz, Carlos A. Valdez, Jim Zapf
Summary: The only medication available to prevent and treat opioid overdose is naloxone, approved by the FDA nearly 50 years ago. Due to its limitations, a scientific meeting was convened by NIAID/NIH to explore emerging alternative approaches for treating opioid overdose in the event of weaponization of synthetic opioids. This meeting discussed new approaches such as intranasal nalmefene, methocinnamox, covalent naloxone nanoparticles, serotonin receptor agonists, fentanyl-binding cyclodextrin scaffolds, detoxifying biomimetic nanosponge decoy receptors, and antibody-based strategies.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Jennifer M. Bossert, E. Andrew Townsend, Lindsay K-P Altidor, Ida Fredriksson, Aniruddha Shekara, Stephen Husbands, Agnieszka Sulima, Kenner C. Rice, Matthew L. Banks, Yavin Shaham
Summary: The study showed that chronic administration of BU08028 reduced the incubation of heroin seeking behavior, but unexpectedly may increase the re-acquisition of heroin self-administration in female rats. In male rats, BU08028 exhibited a selective decrease in extinction responding. Additionally, BU08028 had minimal effects on heroin choice behavior in both sexes.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Joshua C. Zamora, Hudson R. Smith, Elaine M. Jennings, Teresa S. Chavera, Varun Kotipalli, Aleasha Jay, Stephen M. Husbands, Alex Disney, Kelly A. Berg, William P. Clarke
Summary: Opioid overdose is a major cause of death in the United States, with current treatment mainly relying on the competitive antagonist naloxone. However, the short half-life and surmountable antagonism of naloxone limits its effectiveness. Research suggests that the long-lasting, non-surmountable antagonist methocinnamox (MCAM) may offer an improvement in overdose treatment by targeting mu opioid receptors.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2021)
Article
Neurosciences
Andrea Cippitelli, Madeline Martinez, Gilles Zribi, Gerta Cami-Kobeci, Stephen M. Husbands, Lawrence Toll
Summary: This study found that PPL-138 effectively reduces cocaine consumption and relapse in rats. The compound increased locomotor activity in female rats but had no effect on food responses in both sexes. The suppression of cocaine self-administration by PPL-138 could be reversed by blocking mu-opioid receptors but not NOP receptors. Additionally, PPL-138 also reduced the reinstatement of cocaine seeking behavior.
Article
Behavioral Sciences
Lisa R. Gerak, David R. Maguire, Gerta Cami-Kobeci, Keith M. Olson, John R. Traynor, Stephen M. Husbands, Charles P. France, Lisette Acevedo, Barbara Belli, Peter Flynn
Summary: This study explores a multifunctional ligand, OREX-1038, targeting mu opioid and nociceptin/orphanin FQ peptide receptors, and confirms its long-acting antinociceptive effects with limited adverse effects.
BEHAVIOURAL PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Alex Disney, Keith M. Olson, Amanda M. Shafer, Sierra C. Moore, Jessica P. Anand, John R. Traynor, Stephen M. Husbands
Summary: The study designed and synthesized an orvinol antagonist, 14, which showed no agonist activity in vitro, and was at least equally effective as naloxone in reversing the effects of mu-opioid receptor agonists in vivo.
ACS CHEMICAL NEUROSCIENCE
(2022)
Article
Chemistry, Analytical
Rachael C. Andrews, Benedict May, Federico J. Hernandez, Gyles E. Cozier, Piers A. Townsend, Oliver B. Sutcliffe, Tom S. F. Haines, Tom P. Freeman, Jennifer Scott, Stephen M. Husbands, Ian S. Blagbrough, Richard W. Bowman, Simon E. Lewis, Matthew N. Grayson, Rachel Crespo-Otero, David R. Carbery, Christopher R. Pudney
Summary: With the prevalence of synthetic cannabinoid receptor agonist (SCRA) use and the emergence of structurally advanced generations, there is a need for advanced drug detection methods. This study demonstrates the potential of fluorescence spectral fingerprinting (FSF) in rapid SCRA detection. The study also shows the sensitivity of FSFs to structural changes and the identification of specific degradation products.
ANALYTICAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Sarah A. Hindson, Rachael C. Andrews, Michael J. Danson, Marc W. van Der Kamp, Amy E. Manley, Oliver B. Sutcliffe, Tom S. F. Haines, Tom P. Freeman, Jennifer Scott, Stephen M. Husbands, Ian S. Blagbrough, J. L. Ross Anderson, David R. Carbery, Christopher R. Pudney
Summary: Synthetic cannabinoid receptor agonists (SCRAs) are rapidly growing recreational drugs with diverse effects and severe side effects. This study hypothesized that SCRAs may act as monoamine oxidase inhibitors (MAOIs) based on their structural similarity and matching clinical outcomes. Through in silico and experimental studies, it was found that SCRAs are MAO-A-specific inhibitors and their affinity varies depending on the nature of the SCRA 'head' group. This research indicates that SCRA activity is not limited to cannabinoid receptor agonism and suggests alternative interactions to explain their diverse side effects.